Reorganization Entries and Balance Sheet

Reorganization Entries and Balance Sheet

On September 30, 2008, SRP Company filed a petition for reorganization with a bankruptcy court. The plan was approved by the court and all parties of interest on January 2, 2009, when SRP Company’s balance sheet was as follows:

SRP Company Balance Sheet January 2, 2009

Cash$32,000
Accounts receivable$71,450
Less: allowance for uncollectibles16,750
Inventories126,600
Plant & Equipment322,000
Less: Accumulated depreciation180,700141,300
Land20,800
Patents92,000
Total Assets467,600
Current liabilities
Accounts payable-unsecured
12% Notes payable-unsecured57,000
Accrued Wages-with priority11,900
Accured Interest payable38,400
Total current liabilities250,000
10% note payable-unsecured54,400
9% mortgage note payable-secured by equipment80,000

Stockholders’ Equity

Common stock $ .50 par value, 2,500,000

Shares Authorized, $480,000 shares issued and Outstanding 240,000

Retained Earnings (deficit) (156,800)

Total Equities 467,600

The terms of the organization plan are as follows:

1. Creditors represented by $69,000 of the unsecured accounts payable agree to accepts the accounts receivable of SRP Company in full settlements of their claims. The fair value of the receivables is $51,000.

2. Creditors represented by $54,000 of the unsecured accounts payable agree to accept a patent with a book value of $42,000 and a fair value of $50,000 in full settlement of their claims.

3. Creditors of the remaining unsecured accounts payable agree to accept $.60 on the dollar. Cash is paid to these creditors and to the creditors with priority.

4. The creditors holding the 12%, $57,000 note (on which there is $11,900) accrued interest ) agreed to extend the due date for two years from January 3,2009, and to reduce the interest rate to 6% on the current carrying value of the debt ($63,000), payable annually.

5. the holder of the 10%, $54,400 unsecured note (on which these is $11,900 accured interest ) agreed to cancel the accrued interest and $14,400 of the principal; interest on the new note at 10% is due annually, with the principal due on January 3,2012.

6. the holder of the 9%, $80,000 mortgage note (on which there is $20,500 accrued interest) agreed to accept 100,000 shares of the common stock in exchange for full satisfaction of the debt. The common stock had a fair value of $.59 per share.

7. the par value of the common stock is reduced to $.10 per share and any remaining accumulated deficit is eliminated.

Required:

A. Prepare a journal entries to give effect to the reorganization.

B. Prepare a post-reorganization balance sheet dated January 2, 2009

C. Prepare journal entries to accrue interest on December 31, 2009, and to record the payment of interest on January 2, 2010

How much will Grace end up with including the $9 billion cash payment under the base case scenario?

Drug Revolution/Grace Pharmaceuticals Joint Venture Background Information: In early 2018, Kieran Gregory, President and CEO of Drug Revolution, met with members of a joint-venture negotiating team to develop proposed terms of a joint venture agreement. The venture would combine capabilities of Drug Revolution, Inc. and Grace Pharmaceuticals, Inc. Drug Revolution has announced that it is interested in acquiring a 70% share to Zipit a Liquid Filled Capsules from Grace Pharmaceuticals, Inc. Zipit is specifically indicated for the relief of mild to moderate acute pain in adults (18 years of age or older). Zipit is supplied as a 25mg liquid filled capsule for oral administration. The approved dose is 25 mg four times a day. The product uses proprietary delivery technology to deliver a finely dispersed, rapidly absorbed formulation of the drug. The mechanism of action of Zipit, like that of other NSAIDs, is not completely understood but may involve inhibition of the cyclooxygenase (COX-1 and COX-2) pathways. Zipit’s mechanism may also be related to prostaglandin synthetase inhibition. Grace Pharmaceuticals introduced Zipit to the US market the same year it was approved by the FDA. While Grace Pharmaceuticals has done a decent job of marketing Zipit, the company does not have much in the way of extra funds or detailed distribution channels so the sales could potentially be much higher than what Grace has been able to achieve at this point. Drug Revolution is looking to acquire a 70% share in the product in return for an upfront payment to Grace of $9 billion in cash. “We are pleased to expand our portfolio of pain products with the addition of Zipit to our sales force of 164 reps and 78 flex reps that today are detailing Drug Revolution’s small molecule pain medications,” said Kieran Gregory of Drug Revolution. “Zipit is an NSAID that we believe is differentiated in the pain space, allowing rapid absorption of the lowest available oral dose of the drug. Zipit will have an almost immediate positive impact on Drug Revolution’s financials. We believe we will have the runway to achieve significant returns for our shareholders from this joint venture, with the Orange Book listed patent for Zipit expiring in 2033. We plan to utilize our sales force to promote Zipit to pain specialists, neurologists, and high prescribing PCPs, including those we currently detail for our small molecule drug in addition to current prescribers of Zipit.” Grace Pharmaceuticals had been looking for a partner that would contribute cash and marketing expertise in exchange for a share of profits in a joint venture. The joint venture with Grace was attractive to Drug Revolution for several reasons as noted above. Kieran Gregory was eager to conclude a deal with Grace’s board and launch the venture with Grace. Important questions, however, had to be addressed before consummating an agreement. • What was the likely NPV of the joint venture? Gregory wanted the joint venture to be a 70/30 balance of interests between Drug Revolution and Grace Pharmaceuticals. Initial discussions had focused on Drug Revolution paying a lump-sum payment of $9 billion for their 70 percent interest in the venture. Rather than concentrate efforts on the next big hit Drug Revolution had decided to manage its R&D like a portfolio by outsourcing innovations through partnerships. Drug Revolution’s strategy was to supplement its internal R&D with strategic alliances with external companies in order to access high-quality products in late-stage development or recent approval. Because of encouraging results of Grace Pharmaceutical’s limited launch of the drug, management believed that Zipit would be launched full force in the U.S. immediately and in Europe starting 2019. The possible joint venture between Drug Revolution and Grace Pharmaceuticals would concern only the U.S. and European markets. Depending on market conditions (e.g. competition, health-care policies, patents and market need), the remaining life cycle of Zipit drug is estimated at 18 years including year 2018. Market Characteristics The target markets for Grace Pharmaceuticals were patients with mild to moderate arthritis who would be treatable with an NSAID category drug. Drug Revolution’s projections show that there are approximately 250 million current prescriptions filled each year for these types of ailments. Drug Revolution estimates a compounded annual growth rate of 3 percent over the last 10 years, driven by multiple factors including the aging of the population and increases in the incidence of chronic illness. They feel comfortable that the 3% growth rate will continue in the US for the length of the project. Europe has the same number of prescriptions for forecasting purposes, with the prescriptions growing at approximately 2% annually. These growth rates were expected to continue into the near future. Forecast of Income Statements Since many factors vary predictably with the volume of sales, the primary variable forecasted was Zipit revenues. People with aspirin-sensitive asthma or allergic reactions due to aspirin or other NSAIDs should not take Zipit. Prescription Zipit should be used exactly as prescribed at the lowest possible dose for the shortest time needed. The team projects that after being fully rolled out in the U.S. market during 2018 the drug is expected to enter the European market the following year. It is estimated that 60 percent of the U.S. market would be eligible for the drug, while this ratio might be lower (50 percent) for the European market. Many factors are expected to influence revenues. • Peak penetration rate in the market: Based on different marketing analyses and analysts’ reports, the best guess of market penetration for the drug are seen in below: Market 2018 2019 2020 2021 2022 2023 2024 2025 2026 Penetration 7.00% 15.00% 20.00% 35.00% 35.00% 35.00% 35.00% 35.00% 35.00% Market 2027 2028 2029 2030 2031 2032 2033 2034 2035 Penetration 35.00% 35.00% 35.00% 35.00% 35.00% 30.00% 25.00% 20.00% 20.00% • Compliance: Not all patients who use the drug will do so faithfully, even with a doctor strongly recommending its use. The team believes that the most likely compliance rate would be an average of 87 percent. (i.e. The number of actual prescriptions filled in any given year would be equal to (eligible prescriptions)*(percent penetration)*(.87)) • Price per prescription: The annual price of the drug per patient would depend on many things, including how many capsules the patient used and competitive pressures on the price that could be charged for the capsules. The joint-venture team had worked up an estimated figure of $150 as the average cost per prescription filled. The $150 figure is to be used for both the US and European sales. Variable Costs: Although the variable costs of the drug are hard to pinpoint, they are not the most critical variable in the success of the drug. The team members decided to use the industry average of 40% of annual sales revenues to forecast variable costs each year. Fixed Costs: Fixed Costs which would include sales, marketing, and general and administrative expenses are projected as follows (Note: the values are in thousands of dollars): Fixed 2018 2019 2020 2021 2022 2023 2024 2025 2026 Expenses 4,800 6,950 10,500 12,500 15,000 16,250 17,500 18,500 19,500 Fixed 2027 2028 2029 2030 2031 2032 2033 2034 2035 Expenses 20,500 21,500 23,000 22,000 22,000 22,000 22,000 22,000 22,000 Net Working Capital: Net working capital for the joint venture is estimated to comprise a 45-day collection period for receivables, a 90-day period for Zipit inventory, and a 45 day period for payables. Below are the overall changes in net working capital for each year. (Note: the values are in thousands of dollars): Change 2018 2019 2020 2021 2022 2023 2024 2025 2026 In NWC (1,000) (10,000) (13,220) (23,580) (57,770) (84,970) (78,870) (39,930) (21,780) Change 2027 2028 2029 2030 2031 2032 2033 2034 2035 In NWC (23,400) (20,250) (16,070) (17,920) (16,970) (12,420) (3,150) (2,150) (1,000) Capital Expenses and Depreciation Expenses: The team forecasts capital spending of $4.97 billion split over the first three years of the venture (i.e. outflows of $1.75 billion in 2018, $2.42 billion in 2019, and $800 million in 2020). The yearly depreciation used is show below (Note: the values are in thousands of dollars): 2018 2019 2020 2021 2022 2023 2024 2025 2026 Depreciation 105,000 105,000 297,500 297,500 297,500 297,500 297,500 297,500 297,500 2027 2028 2029 2030 2031 2032 2033 2034 2035 Depreciation 297,500 297,500 297,500 297,500 297,500 297,500 297,500 297,500 297,500 Cost of Capital: The last decision that had to be made by the Drug Revolution’s joint-venture team is choosing a required rate of return for discounting the cash flows for the joint venture. The company’s debt currently has a yield to maturity of 10%. The tax rate appropriate for the joint-venture was 30%. Debt constitutes 30% of the cost of capital. Preferred stock usually makes up 10% of all capital and the average current cost of preferred is 14%. Common stock makes up 60% of all capital sources and has an average cost of 16.5%. While the firm expects the drug to be a success they recognize that most new drug ventures come with additional risks and thus have designated a risk premium of 4.6% in addition to the calculated weighted average cost of capital. Capital Budgeting Analysis: 1. Set up the Net Income Statement for the joint venture. 2. Calculate the WACC 3. Calculate the Joint-Venture’s annual cash flows from the project. 4. Calculate the Net Present Value of the enterprise value for the overall project prior to the allocated split in revenues and the 9 billion dollar payment? 5. Assuming Drug Revolution will negotiate a 70% share in the venture and that they pay a lump sum payment of $9 billion in 2018, what is the resulting NPV to Drug Revolution under the base case scenario? 6. How much will Grace end up with including the $9 billion cash payment under the base case scenario? 7. Should Drug Revolution enter into this joint venture using only the base case scenario? Explain your answer. 8. As a way of understanding how sensitive their numbers are to sales forecasts Drug Revolution has decided to analyze the NPV using a sensitivity analysis based off the Total Revenue for all sources of income line on the proforma statement. Drug Revolution will use a +/- 20% of Total Global Sales Revenue to estimate how sensitive their NPV results are to changes in total global revenue. Determine what the NPV for each of these scenarios would be. 9. Assume the base case is assigned a probability of occurrence of 60%. Also assume that the best and worst case scenarios have probabilities of 10% and 30% respectively. Given above adjustments what would the expected NPV for Drug Revolution be? Should this analysis adjust your recommendations of an accept/reject decision for Drug Revolution? 10. What are some of the other methods that are used to evaluate investment projects and compare them to NPV? No specific calculations here, just a discussion. Explain some of the potential drawbacks in this specific case with using the other investment evaluation methods. 11. Would it be possible to calculate the IRR of this joint-venture? You do not have to do the calculation, but discuss if it is possible to do and if there would be a problem calculating the IRR in this specific problem. Appendix 1: Sample First Year Proforma Income Statement Forecasted Income Statement ($000’s) Joint-Venture 2016 Market Penetration U.S. Market prescriptions filled Eligibility Total Eligible U.S. prescriptions European Market prescriptions filled Eligibility Total Eligible European Prescriptions Total Customer Base Both Markets Total Revenues($000) Variable Costs (000’s) Fixed Expenses (000’s) Depreciation (000’s) EBIT (000’s) Tax (@30%)* Net Income (000’s) * Note: Assume there is no tax effect if EBIT is negative. Appendix 2: Sample Free Cash Flow Calculation Drug Revolution/Grace Pharm Joint-Venture Forecast of Cash Flows (000’s) 2016 Net Income Add back depreciation Net Operating Cash Flow Net Working Capital Change in NWC Recovery of NWC Total Change in NWC Capital Spending Initial Outlay Free Cash Flow:

Drug Revolution/Grace Pharmaceuticals Joint Venture

Background Information:

In early 2018, Kieran Gregory, President and CEO of Drug Revolution, met with members of a joint-venture negotiating team to develop proposed terms of a joint venture agreement. The venture would combine capabilities of Drug Revolution, Inc. and Grace Pharmaceuticals, Inc. Drug Revolution has announced that it is interested in acquiring a 70% share to Zipit a Liquid Filled Capsules from Grace Pharmaceuticals, Inc. Zipit is specifically indicated for the relief of mild to moderate acute pain in adults (18 years of age or older). Zipit is supplied as a 25mg liquid filled capsule for oral administration. The approved dose is 25 mg four times a day. The product uses proprietary delivery technology to deliver a finely dispersed, rapidly absorbed formulation of the drug. The mechanism of action of Zipit, like that of other NSAIDs, is not completely understood but may involve inhibition of the cyclooxygenase (COX-1 and COX-2) pathways. Zipit’s mechanism may also be related to prostaglandin synthetase inhibition.

Grace Pharmaceuticals introduced Zipit to the US market the same year it was approved by the FDA. While Grace Pharmaceuticals has done a decent job of marketing Zipit, the company does not have much in the way of extra funds or detailed distribution channels so the sales could potentially be much higher than what Grace has been able to achieve at this point. Drug Revolution is looking to acquire a 70% share in the product in return for an upfront payment to Grace of $9 billion in cash.

“We are pleased to expand our portfolio of pain products with the addition of Zipit to our sales force of 164 reps and 78 flex reps that today are detailing Drug Revolution’s small molecule pain medications,” said Kieran Gregory of Drug Revolution. “Zipit is an NSAID that we believe is differentiated in the pain space, allowing rapid absorption of the lowest available oral dose of the drug. Zipit will have an almost immediate positive impact on Drug Revolution’s financials. We believe we will have the runway to achieve significant returns for our shareholders from this joint venture, with the Orange Book listed patent for Zipit expiring in 2033. We plan to utilize our sales force to promote Zipit to pain specialists, neurologists, and high prescribing PCPs, including those we currently detail for our small molecule drug in addition to current prescribers of Zipit.”

Grace Pharmaceuticals had been looking for a partner that would contribute cash and marketing expertise in exchange for a share of profits in a joint venture.

The joint venture with Grace was attractive to Drug Revolution for several reasons as noted above. Kieran Gregory was eager to conclude a deal with Grace’s board and launch the venture with Grace. Important questions, however, had to be addressed before consummating an agreement.

What was the likely NPV of the joint venture? Gregory wanted the joint venture to be a 70/30 balance of interests between Drug Revolution and Grace Pharmaceuticals. Initial discussions had focused on Drug Revolution paying a lump-sum payment of $9 billion for their 70 percent interest in the venture.

Rather than concentrate efforts on the next big hit Drug Revolution had decided to manage its R&D like a portfolio by outsourcing innovations through partnerships. Drug Revolution’s strategy was to supplement its internal R&D with strategic alliances with external companies in order to access high-quality products in late-stage development or recent approval. Because of encouraging results of Grace Pharmaceutical’s limited launch of the drug, management believed that Zipit would be launched full force in the U.S. immediately and in Europe starting 2019. The possible joint venture between Drug Revolution and Grace Pharmaceuticals would concern only the U.S. and European markets. Depending on market conditions (e.g. competition, health-care policies, patents and market need), the remaining life cycle of Zipit drug is estimated at 18 years including year 2018.

Market Characteristics

The target markets for Grace Pharmaceuticals were patients with mild to moderate arthritis who would be treatable with an NSAID category drug. Drug Revolution’s projections show that there are approximately 250 million current prescriptions filled each year for these types of ailments. Drug Revolution estimates a compounded annual growth rate of 3 percent over the last 10 years, driven by multiple factors including the aging of the population and increases in the incidence of chronic illness. They feel comfortable that the 3% growth rate will continue in the US for the length of the project. Europe has the same number of prescriptions for forecasting purposes, with the prescriptions growing at approximately 2% annually. These growth rates were expected to continue into the near future.

Forecast of Income Statements

Since many factors vary predictably with the volume of sales, the primary variable forecasted was Zipit revenues. People with aspirin-sensitive asthma or allergic reactions due to aspirin or other NSAIDs should not take Zipit. Prescription Zipit should be used exactly as prescribed at the lowest possible dose for the shortest time needed. The team projects that after being fully rolled out in the U.S. market during 2018 the drug is expected to enter the European market the following year. It is estimated that 60 percent of the U.S. market would be eligible for the drug, while this ratio might be lower (50 percent) for the European market. Many factors are expected to influence revenues.

Peak penetration rate in the market: Based on different marketing analyses and analysts’ reports, the best guess of market penetration for the drug are seen in below:

Market201820192020202120222023202420252026
Penetration7.00%15.00%20.00%35.00%35.00%35.00%35.00%35.00%35.00%
Market202720282029203020312032203320342035
Penetration35.00%35.00%35.00%35.00%35.00%30.00%25.00%20.00%20.00%

Compliance: Not all patients who use the drug will do so faithfully, even with a doctor strongly recommending its use.   The team believes that the most likely compliance rate would be an average of 87 percent. (i.e. The number of actual prescriptions filled in any given year would be equal to (eligible prescriptions)*(percent penetration)*(.87))

Price per prescription: The annual price of the drug per patient would depend on many things, including how many capsules the patient used and competitive pressures on the price that could be charged for the capsules. The joint-venture team had worked up an estimated figure of $150 as the average cost per prescription filled. The $150 figure is to be used for both the US and European sales.

Variable Costs:

Although the variable costs of the drug are hard to pinpoint, they are not the most critical variable in the success of the drug. The team members decided to use the industry average of 40% of annual sales revenues to forecast variable costs each year.

Fixed Costs:

Fixed Costs which would include sales, marketing, and general and administrative expenses are projected as follows (Note: the values are in thousands of dollars):

Fixed201820192020202120222023202420252026
Expenses4,8006,95010,50012,50015,00016,25017,50018,50019,500
Fixed202720282029203020312032203320342035
Expenses20,50021,50023,00022,00022,00022,00022,00022,00022,000

Net Working Capital:

Net working capital for the joint venture is estimated to comprise a 45-day collection period for receivables, a 90-day period for Zipit inventory, and a 45 day period for payables. Below are the overall changes in net working capital for each year. (Note: the values are in thousands of dollars):

Change201820192020202120222023202420252026
In NWC(1,000)(10,000)(13,220)(23,580)(57,770)(84,970)(78,870)(39,930)(21,780)
Change202720282029203020312032203320342035
In NWC(23,400)(20,250)(16,070)(17,920)(16,970)(12,420)(3,150)(2,150)(1,000)

Capital Expenses and Depreciation Expenses:

The team forecasts capital spending of $4.97 billion split over the first three years of the venture (i.e. outflows of $1.75 billion in 2018, $2.42 billion in 2019, and $800 million in 2020). The yearly depreciation used is show below (Note: the values are in thousands of dollars):

201820192020202120222023202420252026
Depreciation105,000105,000297,500297,500297,500297,500297,500297,500297,500
202720282029203020312032203320342035
Depreciation297,500297,500297,500297,500297,500297,500297,500297,500297,500

Cost of Capital:

The last decision that had to be made by the Drug Revolution’s joint-venture team is choosing a required rate of return for discounting the cash flows for the joint venture. The company’s debt currently has a yield to maturity of 10%. The tax rate appropriate for the joint-venture was 30%. Debt constitutes 30% of the cost of capital. Preferred stock usually makes up 10% of all capital and the average current cost of preferred is 14%. Common stock makes up 60% of all capital sources and has an average cost of 16.5%. While the firm expects the drug to be a success they recognize that most new drug ventures come with additional risks and thus have designated a risk premium of 4.6% in addition to the calculated weighted average cost of capital.

Capital Budgeting Analysis:

Set up the Net Income Statement for the joint venture.

Calculate the WACC

Calculate the Joint-Venture’s annual cash flows from the project.

Calculate the Net Present Value of the enterprise value for the overall project prior to the allocated split in revenues and the 9 billion dollar payment?

Assuming Drug Revolution will negotiate a 70% share in the venture and that they pay a lump sum payment of $9 billion in 2018, what is the resulting NPV to Drug Revolution under the base case scenario?

How much will Grace end up with including the $9 billion cash payment under the base case scenario?

Should Drug Revolution enter into this joint venture using only the base case scenario? Explain your answer.

As a way of understanding how sensitive their numbers are to sales forecasts Drug Revolution has decided to analyze the NPV using a sensitivity analysis based off the Total Revenue for all sources of income line on the proforma statement. Drug Revolution will use a +/- 20% of Total Global Sales Revenue to estimate how sensitive their NPV results are to changes in total global revenue. Determine what the NPV for each of these scenarios would be.

Assume the base case is assigned a probability of occurrence of 60%. Also assume that the best and worst case scenarios have probabilities of 10% and 30% respectively. Given above adjustments what would the expected NPV for Drug Revolution be? Should this analysis adjust your recommendations of an accept/reject decision for Drug Revolution?

What are some of the other methods that are used to evaluate investment projects and compare them to NPV? No specific calculations here, just a discussion. Explain some of the potential drawbacks in this specific case with using the other investment evaluation methods.

Would it be possible to calculate the IRR of this joint-venture? You do not have to do the calculation, but discuss if it is possible to do and if there would be a problem calculating the IRR in this specific problem.
Appendix 1: Sample First Year Proforma Income Statement

Forecasted Income Statement ($000’s)
Joint-Venture
2016
Market Penetration
U.S. Market prescriptions filled
Eligibility
Total Eligible U.S. prescriptions
European Market prescriptions filled
Eligibility
Total Eligible European Prescriptions
Total Customer Base Both Markets
Total Revenues($000)
Variable Costs (000’s)
Fixed Expenses (000’s)
Depreciation (000’s)
EBIT (000’s)
Tax (@30%)*
Net Income (000’s)
* Note: Assume there is no tax effect if EBIT is negative.

Appendix 2: Sample Free Cash Flow Calculation

Drug Revolution/Grace Pharm Joint-Venture
Forecast of Cash Flows (000’s)
2016
Net Income
Add back depreciation
Net Operating Cash Flow
Net Working Capital
Change in NWC
Recovery of NWC
Total Change in NWC
Capital Spending
Initial Outlay

Free Cash Flow:

When companies develop new technologies, they can never be certain how the market will respond. That said, the future of a given technology is not as unforeseeable as it might seem.

Introduction summray and conclusion 500 words from the below document.

When companies develop new technologies, they can never be certain how the market will respond. That said, the future of a given technology is not as unforeseeable as it might seem. When I work with tech companies on crafting or refining their innovation strategy, I start with an exercise that helps them anticipate where the next big breakthroughs will—or should—be. Central to the exercise is an examination of the key dimensions on which a technology has evolved—say, processing speed in computing—and the degree to which users’ needs have been satisfied. This can give companies insight into where to focus their effort and money while helping them anticipate both the moves of competitors and threats from outsiders.

One of my favorite examples comes from the consumer electronics and recording industries, which competed on the basis of audio fidelity for decades. By the mid-1990s, both industries were eager to introduce a next-generation audio format. In 1996 Toshiba, Hitachi, Time Warner, and others formed a consortium to back a new technology, called DVD-Audio, that offered superior fidelity and surround sound. They hoped to do an end run around Sony and Philips, which owned the compact disc standard and extracted a licensing fee for every CD and player sold.

Sony and Philips, however, were not going to go down without a fight. They counterattacked with a new format they had jointly developed, Super Audio CD. Those in the music industry gave a collective groan; manufacturers, distributors, and consumers all stood to lose big if they bet on the wrong format. Nonetheless, Sony launched the first Super Audio players in late 1999; DVD-Audio players hit the market in mid-2000. A costly format war seemed inevitable.

You may be scratching your head at this point, wondering why you’ve never heard about this format war. What happened? MP3 happened. While the consumer electronics giants were pursuing new heights in audio fidelity, an algorithm that slightly depressed fidelity in exchange for reduced audio file size was taking off. Soon after the file-sharing platform Napster launched in 1999, consumers were downloading free music files by the millions, and Napster-like services were sprouting up like weeds.

You might be inclined to think that Sony, Philips, and the DVD-Audio consortium were just unlucky. After all, who could have predicted the disruptive arrival of MP3? How could the consumer electronics giants have known that a format on a trajectory of ever-increasing fidelity would be overtaken by a technology with less fidelity? Actually, with the methodology outlined below, they could have foreseen that the next breakthrough would probably not be about better fidelity.

Understanding what’s driving technological developments isn’t just for high-tech firms. Technology—the way inputs are transformed into outputs, or the way products and services are delivered to customers—evolves in every market. I have used the three-step exercise described here with managers from a wide range of organizations, including companies developing blood-sugar monitors, grocery store chains, hospitals, a paint-thinner manufacturer, and financial services firms. It often yields an “Aha!” moment that helps managers refine or even redirect their innovation strategy.

Step One: Identify Key Dimensions

It’s common to talk about a “technology trajectory,” as if innovation advances along a single path. But technologies typically progress along several dimensions at once. For example, computers became faster and smaller in tandem; speed was one dimension, size another. Developments in any dimension come with specific costs and benefits and have measurable and changing utility for customers. Identifying the key dimensions of a technology’s progression is the first step in predicting its future.

To determine these dimensions, trace the technology’s evolution to date, starting as far back as possible. Consider what need the technology originally fulfilled, and then for each major change in its form and function, think about what fundamental elements were affected.

To illustrate, let’s return to music-recording technology. Tracing its history reveals six dimensions that have been central to its development: desynchronization, cost, fidelity, music selection, portability, and customizability. Before the invention of the phonograph, people could hear music or a speech only when and where it was performed. When Thomas Edison and Alexander Graham Bell began working on their phonographs in the late 1800s, their primary objective was to desynchronize the time and place of a performance so that it could be heard anytime, anywhere. Edison’s device—a rotating cylinder covered in foil—was a remarkable achievement, but it was cumbersome, and making copies was difficult. Bell’s wax-covered cardboard cylinders, followed by Emile Berliner’s flat, disc-shaped records and, later, the development of magnetic tape, made it significantly easier to mass-produce recordings, lowering their cost while increasing the fidelity and selection of music available.

For decades, however, players were bulky and not particularly portable. It was not until the 1960s that eight-track tape cartridges dramatically increased the portabilityof recorded music, as players became common in automobiles. Cassette tapes rose to dominance in the 1970s, further enhancing portability but also offering, for the first time, customizability—the ability to create personalized playlists. Then, in 1982, Sony and Philips introduced the compact disc standard, which offered greater fidelity than cassette tapes and rapidly became the dominant format.

When I guide executive teams through step one of the exercise, I emphasize the need to zero in on the high-level dimensions along which a technology has evolved—those that are broad enough to encompass other, narrower dimensions. This helps teams see the big picture and avoid getting sidetracked by its details. In audio technology, for example, recordability is a specific form of customizability; identifying customizability, rather than the narrower recordability, as a high-level dimension invites exploration of other ways people might want to customize their music experience. For example, they might value a technology that automatically generates a playlist of songs with common characteristics—and indeed, services like Pandora and Spotify emerged to do just that.

Selecting useful dimensions to examine takes industry knowledge and common sense.

It’s important to identify dimensions at the optimal “altitude”—neither so low or narrow that they miss the big picture, nor so high or broad that they won’t offer adequately detailed insight about a specific technology. In the case of automobiles, for example, climate control may be a technology dimension, but it’s so narrow that it’s not the most useful one to study; examining the higher-level “comfort” dimension under which it falls will be more illuminating. By the same token, the sweeping “performance” dimension in automobiles is probably too broad a choice, because it includes speed, safety, fuel efficiency, and other dimensions where meaningful advances could be made. Even a product as simple as a mattress involves technology with multiple performance dimensions—such as comfort and durability—that are useful to consider separately.

Selecting dimensions to examine isn’t a strict science; it depends substantially on knowledge of your industry—and common sense. I usually ask teams to agree on three to six key dimensions for their technology. The exhibit “A Sampling of High-Level Technology Dimensions” lists those identified by workshop participants for their respective industries. Notably, some dimensions, such as ease of use and durability, come up frequently. Others are more specific to a particular technology, such as magnification in microscopes. And with rare exceptions, cost is an important dimension across all technologies.

A Sampling of High-Level Technology Dimensions

READ MORE

A final step in this part of the exercise can add further insight about the identified dimensions and in some cases suggest future dimensions worth exploring. I ask team members to disregard cost and other constraints and imagine what customers would want if they could have anything.This sounds like it might unleash a flood of creative but impractical ideas. In fact, it can be highly revealing. Folklore has it that Henry Ford once said, “If I had asked people what they wanted, they would have said faster horses.” If any carmaker at the time had really probed people about exactly what their dream conveyance would provide, they probably would have said “instantaneous transportation.” Both consumer responses highlight that speed is a high-level dimension valued in transportation, but the latter helps us think more broadly about how it can be achieved. There are only limited ways to make horses go faster—but there are many ways to speed up transportation.

Most of the time this exercise indicates that people want further improvements in the key dimensions already identified. Sometimes, however, the exercise suggests dimensions that have not been considered. Would consumers want an audio device that could sense and respond to their affect? If so, perhaps “anticipation of needs” is another key dimension.

Step Two: Locate Your Position

For each dimension, you next want to determine the shape of its utility curve—the plot of the value consumers derive from a technology according to its performance—and establish where on the curve the technology currently sits. This will help reveal where the greatest opportunity for improvement lies.

For example, the history of audio formats suggests that the selection of music available has a concave parabolic utility curve: Utility increases as selection expands, but at a decreasing rate, and not indefinitely. When there’s little music to choose from, even a small increase in selection significantly enhances utility. Consider that when the first phonographs appeared, there were few recordings to play on them. As more became available, customers eagerly bought them, and the appeal of owning a player grew. Increasing selection even a little had a powerful impact on utility. Over the ensuing decades, selection grew exponentially, and the utility curve ultimately began to flatten; people still valued new releases, but each new recording added less additional value. Today digital music services like iTunes, Amazon Prime Music, and Spotify offer tens of millions of songs. With this virtually unlimited selection, most customers’ appetites are sated—and we are probably approaching the top of the curve.

More Music, More Value—Up to a Point

For some technologies, small improvements can have a big impact at first. In the early days of recorded music, listeners had few pieces to choose from, so the utility of increasing the selection even a small amount was high. Today consumers have virtually unlimited choices, so the additional utility of increasing selection is low.

Now let’s consider the fidelity dimension, the primary focus of Super Audio CD and DVD-Audio. It’s likely that fidelity also has a concave parabolic utility curve. The first phonographs had awful fidelity: Music sounded thin and tinny, though it was still a remarkable benefit to be able to hear any recorded music at all. The early improvements in fidelity that records offered made a big difference in people’s enjoyment of music, and sales took off. Then along came compact discs. The higher fidelity they offered was not as widely appreciated—many people felt that vinyl records were good enough, and some even preferred their “warmth.” For most consumers, further improvements in fidelity provided little additional utility. The fidelity curve was already leveling out when Sony, Philips, and the DVD-Audio consortium introduced their new formats in the early 2000s.

Both formats offered higher fidelity, by certain technical measures, than the compact disc. For example, whereas CDs have a frequency range up to about 20,000 cycles per second, or 20 kHz, the new formats offered ranges that reached 50 kHz. That’s an impressive high end—but because human hearing peaks out at about 20 kHz, only the family dog was likely to appreciate it. In 2007 the Audio Engineering Society released the results of a yearlong trial assessing how well subjects (including professional recording engineers) could detect the difference between Super Audio and regular CDs. Subjects correctly identified the Super Audio CD format only half the time—no better than if they’d been simply guessing.

Had the companies introducing the new formats created even a back-of-the-envelope utility curve for fidelity, they could have seen that there was little room for improvement that customers would appreciate. Meanwhile, even a cursory look at the portability curve would have suggested opportunity on that dimension. Sony, of all companies, should have recognized the importance of portability in the evolution of audio formats. Back in 1979, the company had introduced one of the most successful consumer electronics products ever created—the Sony Walkman. The device, a lightweight cassette player that could fit in one hand, was a runaway hit not because it cost less or offered greater fidelity or selection than other formats but because it was portable. Similarly, MP3 was successful because it made music much more portable; MP3 files were small enough to be easily stored on a computer and shared with friends.

Only the family dog was apt to appreciate further improvements in audio fidelity.

Fast-forward to today. Although music lovers now take portability and selection for granted, there’s still lots of room for improvement on the customizability dimension. Pandora offers primitive customizability (you can create a channel where all the songs sound more or less like Taylor Swift), but artificial intelligence may get us much further up that utility curve in the future. It’s plausible (likely, in fact) that a program could identify elements of your preferred music style and then create music for you. Perhaps it would produce an endless stream of “Beatles songs,” nearly indistinguishable from the real thing but not written or played by the Beatles (or by any human performer). Machine-learning programs already compose music for advertisements and video games, and in 2016 Sony released two songs composed by an artificial intelligence system called Flow Machines. The first, “Daddy’s Car,” is reminiscent of the Beatles, and the second, “Mr Shadow,” emulates the styles of Duke Ellington, Irving Berlin, and Cole Porter. While neither quite hits the mark, both suggest what’s to come—and where music companies might sensibly invest.

Parabolic utility curves like those for audio fidelity and selection show that for some technology performance dimensions, small improvements can have a dramatic impact on utility from the start. Of course, not all technologies follow such utility curves.

High Demand for Drugs That Work

For some technologies, consumers prize even modest advances. Only one of the approved treatments for the neurodegenerative disease ALS extends life span—and only by a few months. Patient demand for effective drugs won’t be satisfied until efficacy is 100%, but any improvement up to that point has high utility.

Many dimensions have S-shaped curves: Below some threshold of performance there is no utility, but utility increases quickly above that threshold and then maxes out somewhere beyond that. Consider the utility of a car’s speed for an average customer. The first motor vehicles, such as Richard Trevithick’s 1801 Puffing Devil, were steam-powered. They offered a proof of concept and were sometimes purchased by wealthy technophiles, but they were too slow and unreliable to be worth the cost to the average family. Horses traveled farther and faster and rarely broke down.

For the next hundred years, inventors sought to develop an automobile that was more useful than a horse-drawn wagon. During this time, the utility curve for speed remained flat; increasing a car’s top speed by a few miles an hour offered no additional utility if the car was still slower than a horse—particularly if it was also less reliable, as was typically the case. It wasn’t until the early 20th century, when passenger automobiles started to routinely offer speeds over 15 miles per hour, that they began to be adopted in serious numbers. By the 1990s most passenger cars had a top speed of about 120 mph, and today for many it’s near 150 mph. It’s uncommon, however, for drivers to exceed 90 mph; for most drivers, the utility curve for speed flattens out at that point. Improvements in other dimensions, such as fuel efficiency, acceleration, safety, and reliability, offer more utility to most customers.

The Car-Speed Sweet Spot

Some technology improvements have little appeal early on and then quickly grow in value before their utility levels off. The first cars were too slow to be very useful. As they became faster and roads improved, consumers valued ever-greater top speeds—up to about 90 miles per hour. Beyond that, extra speed makes no difference to most drivers.

The utility curve for speed reveals that the point at which improvements in a dimension are of little value can change with shifts in the environment or in enabling technologies. Forty miles per hour probably seemed more than fast enough, for example, when the Model T was introduced, since most roads at the time weren’t paved. As roads improved and highways appeared, the top speeds desired by customers shifted upward. The move to autonomous vehicles may make even higher speeds safe, comfortable, and desirable. If so, the flat top of the current utility curve for speed may slope upward once again.

Step Three: Determine Your Focus

Once you know the dimensions along which your firm’s technology has (or can be) improved and where you are on the utility curves for those dimensions, it should be straightforward to identify where the most room for improvement exists. But it’s not enough to know that performance on a given dimension can be enhanced; you need to decide whether it should be. So first assess which of the dimensions you’ve identified are most important to customers. Then assess the cost and difficulty of addressing each dimension.

For example, of the four dimensions that have been central to automobile development—speed, cost, comfort, and safety—which do customers value most, and which are easiest or most cost-effective to address? On the speed dimension, cars are already at the top of the utility curve, and top speed is relatively difficult and expensive to increase: Higher speed requires more power, which requires a bigger engine, which reduces fuel efficiency and increases cost. Comfort is probably the easiest dimension to address, but is it as important to consumers as safety? And how much does it cost to improve performance on these dimensions?

Tata Motors’ experience with the Nano is instructive. The Nano was designed as an affordable car for drivers in India, so it needed to be cheap enough to compete with two-wheeled scooters. The manufacturer cut costs in several ways: The Nano had only a two-cylinder engine and few amenities—no radio, electric windows or locks, antilock brakes, power steering, or airbags. Its seats had a simple three-position recline, the windshield had a single wiper, and there was only one rearview mirror. In 2014, after the Nano received zero stars for safety in crash tests, analysts pointed out that adding airbags and making simple adjustments to the frame could significantly improve the car’s safety for less than $100 per vehicle. Tata took this under advisement—and placed its bets on comfort. All 2017 models include air-conditioning and power steering but not airbags.

How to Improve Glucose Monitoring?

READ MORE

To assess which technology investments are likely to yield the biggest bang for the buck, managers can use a matrix like the one in the exhibit “How to Improve Glucose Monitoring?” First, for the technology being examined, list the performance dimensions you’ve identified as most important. (For cars, for example, that might be cost, safety, and comfort.) Then score each dimension on a scale of 1 to 5 in three areas:

Importance to customers (1 = “not important” and 5 = “very important”)
Room for improvement (1 = “minor opportunity” and 5 = “major opportunity”)
Ease of improvement (1 = “very difficult” and 5 = “very easy”)

The exhibit shows a manufacturer’s scores on four dimensions of blood-glucose monitors: reliability, comfort, cost, and ease of use. The team identified reliability as most important to customers; having accurate glucose measures can be a matter of life and death. However, existing devices (most of which require a finger prick) are already very reliable and thus scored low on the “room for improvement” measure. They are also fairly easy to use and reasonably low in cost—but they are uncomfortable. Comfort is highly valued yet has much room for improvement. Both comfort and ease of use are moderately difficult to improve (scoring 3s), but because comfort is more important to customers and has more room for improvement, this dimension received the higher total score. So comfort became the focus for innovation efforts; the company began to develop a patch worn on the skin that would detect glucose levels from sweat and would send readings via Bluetooth to the user’s smartphone.

From Exercise to Innovation

READ MORE

Notably, with a simple manipulation, the weight of the matrix scores can be adjusted to reflect any organization’s particular situation. For example, if a company is cash-strapped or under other duress, it may want to prioritize easy-to-improve dimensions rather than pursue those that have the greatest potential but are harder to address. If the scale for ease of improvement is switched to 1–10 (while the other scales are kept at 1–5), ease-of-improvement scores can be expected to roughly double and thus have a greater influence on total scores. Alternatively, a company seeking breakthrough innovation might extend the scale for importance to buyers, the scale for room for improvement, or both.

Getting an Edge on Competitors

READ MORE

Similarly, a company’s competitive positioning may affect which technology dimensions it emphasizes. For example, safety may be a key differentiator for an automaker such as Volvo, while speed (or, more broadly, driving performance) may be the differentiator for BMW. So although the companies make the same technology (cars), they market to different customer segments and thus emphasize different dimensions.

Shifting the Focus

The three-part exercise I recommend can help managers broaden their perspective on their industry and shift their focus from “This is what we do” to “This is where our market is (or should be) heading.” It can also help overcome the bias and inertia that tend to keep an organization’s attention locked on technology dimensions that are less important to consumers than they once were. For example, at a large financial services firm I worked with, data-transfer speed had long been a key dimension where the leadership expected to see regular improvements. At its founding, the firm had developed technology to deliver financial data more rapidly than anyone else could. Being faster than competitors was, and remained, central to the company’s strategy and a matter of organizational pride. However, when I used this exercise with the firm’s managers, they realized that concentrating on data-transfer speed (which was now in the nanoseconds) was diverting their attention away from technology dimensions where there was greater opportunity to make improvements that customers would actually value.

For this firm, data-transfer speed had become what fidelity was to Super Audio CD: It could be improved upon year after year, but it offered diminishing utility to users. Furthermore, speed no longer provided a competitive advantage; technology to move data quickly had become ubiquitous and commoditized. The firm’s proprietary algorithms for transforming raw data into strategically useful information were far more defensible. The exercise revealed much greater opportunity for delivering this information on demand. Following the workshop, a group of managers made plans to shift resources into ensuring that their most highly used and differentiated analytics-based products could be effectively delivered on phones and tablets. The result was an award-winning mobile application that is now among the top three financial-services applications worldwide.

CONCLUSION

New product ideas are not the only—or even the most important—outcome of this exercise. Perhaps more valuable is the big-picture perspective it can give managers—shedding new light on market dynamics and the larger-scale or longer-term opportunities before them. Only then will they be able to lead innovation in their industries rather than scramble to respond to it.

Restaurant Meal Analysis

Project – Restaurant Meal Analysis

Use red font to write your answers and explanations on this Word document. All final answers, charts, graphs should be in the Word document. However, you will submit this Word document and the Excel spreadsheet to the 5.5 Dropbox.

Pick your favorite restaurant, and do a web search for the nutrition facts for its menu items. Most restaurants have this information available. If you can’t find the nutrition facts, choose another restaurant.

(15 pts) Choose 10 entrees and record the following information. Then create an Excel spreadsheet to display these values and make sure to save it to your computer. Use an Excel formula to find the mean for each category.

Name of Restaurant: Burger King
Item NameCaloriesTotal fat (g)Sodium (mg)Carbohydrate (g)Protein (g)
WHOPPER® Sandwich660409804928
WHOPPER JR.® Sandwich310183902713
Cheeseburger280135602715
Double Cheeseburger390215902723
Grilled Chicken Sandwich470198503937
Chicken Nuggets- 4pc17011310118
Original Chicken Sandwich6604011704828
RODEO® Crispy Chicken Sandwich9606022307233
French Fries – medium (Salted)38017570535
Garden Side Salad – w/o dressing6049534
Mean43424.3774.535.619.4

(3 pts) Choose your favorite entrée and fill in the chart.

Favorite entréeCaloriesTotal fat (g)Carbohydrate (g)Protein (g)
Double Cheeseburger390212723

(3 pts) Assume that one serving of fat is approximately 5 g, one serving of protein is approximately 7 g, and one serving of carbohydrates is approximately 15 g. Then determine how many servings of fat, protein, and carbohydrates are in that entrée.

Show your work here:

(3 pts) Look up how many servings are recommended per day (remember to cite your source). Record this information along with the results from Question 3 in the table below.

FatProteinCarb
Number of Servings in your Entrée
Daily Recommended Servings
Source:

(3 pts) Use Excel to create a double (or “clustered”) bar graph that compares the number of servings in your entrée to the number of recommended daily servings. Include labels.

Paste the double bar graph here:

(3 pts) Look up how many calories are in one gram of fat, protein, and carbohydrates (remember to cite your source). Write these values and the website you used here:

1 gram Fat1 gram Protein1 gram Carb
Source:

(3 pts) Determine how many calories in your chosen entrée come from fat, protein, carbohydrates, and other.

Show your work here:

(3 pts) Convert these to percentages of the total calories in the entrée and use Excel to create a pie chart. Include labels.

Paste your pie chart here:

(15 pts) Determine the total calories in the entrée. Assume you consumed a 300 calorie breakfast, a 600 calorie lunch, and this entrée for dinner. If you ate this meal every day for 1 year (365 days), how would this effect your life and body (weight, health, etc)?

Your response needs to be at least 300 words.

Base your answer on these assumptions

You should consume 2000 calories per day.

One pound of weight gain or loss is equivalent to 3500 calories.

You do not have any food allergies.

Explain and show any work needed for this calculation.

Describe the assumptions in making your judgments.

Provide compelling rationale for why each assumption is appropriate or inappropriate.

Explain whether and how your findings are valid.

Explain whether and how your findings are reasonable.

Provide deep and thoughtful judgments, drawing insightful, carefully qualified conclusions from the project.

(3 pts) Describe how this project fulfills the Gen Ed Outcomes (Interpretation, Representation, Calculation, Application/Analysis, Assumptions, Communication).

(3 pts) Describe how this MAT-118 course is essential for one’s professional education program as well as expanding other long-term career path options.

(3 pts) All final answers, charts, graphs should be in the Word document. Submit this Word document and the Excel spreadsheet to the 5.5 Dropbox.